#United States #San Diego #class action lawsuit #deramiocel #Capricor Therapeutics

Overview of the Class Action Lawsuit

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology firm specializing in therapies for Duchenne muscular dystrophy, is currently embroiled in a class action lawsuit initiated by Robbins Geller Rudman & Dowd LLP. The legal action stems from substantial financial losses incurred by investors who purchased shares between December 17, 2025, and July 26, 2026. This lawsuit, properly titled Nkamga v. Capricor Therapeutics, Inc., seeks to appoint a lead plaintiff, with a deadline set for September 28, 2026.

Allegations Against Capricor

The primary allegations focus on misleading statements made by Capricor’s executives regarding the company’s lead drug candidate, Deramiocel, which is intended to treat cardiac and skeletal muscle complications in patients suffering from Duchenne muscular dystrophy. The lawsuit claims that Capricor failed to disclose crucial modifications to the pre-specified statistical analysis plan (SAP) used for clinical trials. These changes were supposedly made without the agreement of the FDA prior to the resubmission of the drug’s Biologics License Application (BLA). The lawsuit highlights a significant risk that the FDA might conclude the clinical data did not substantiate the drug's effectiveness, thus jeopardizing the drug's approval.

Impacts on Stock and Investor Confidence

The fallout from these developments has been severe. After the FDA released briefing documents detailing these allegations, Capricor's stock plummeted by 64%, greatly diminishing investor confidence. The briefing indicated that the final version of the SAP was created just a day before the data was unraveled, raising serious questions about the validity and integrity of the clinical results. Subsequently, during a July 29 advisory committee meeting, the panel expressed skepticism about Deramiocel’s efficacy, leading to a further drop of 36% in share price following the meeting.

The Role of Class Action and What It Means for Investors

Under the Private Securities Litigation Reform Act of 1995, any investor who sustained losses during the Class Period can seek to be designated as the lead plaintiff. This position is significant; the lead plaintiff represents the interests of all investors in the class and selects legal counsel for the case. Importantly, participation as the lead plaintiff does not affect an investor’s share of any eventual recovery, meaning that all class members can benefit from any settlement or judgment, regardless of their role in the lawsuit.

Robbins Geller Rudman & Dowd LLP’s Involvement

Robbins Geller is recognized as a leading law firm representing investors in cases of securities fraud and shareholder rights. The firm has demonstrated a strong track record, recovering over $916 million for investors in 2025 alone, and achieving recognition as the top firm for securities class action services multiple times over the past few years. Their involvement in this case reflects their commitment to protecting investors’ rights and ensuring that allegations of misconduct are thoroughly addressed in the courts.

Conclusion

For those who have invested in Capricor Therapeutics during the designated Class Period, there lies an opportunity to hold the company accountable for its alleged misleading practices that have contributed to significant financial losses. The upcoming months will be critical for the future of this lawsuit, as the search for a lead plaintiff gains momentum. If you believe you have been affected, you are encouraged to gather your information and consult with the legal representatives at Robbins Geller who are spearheading this important case. By joining forces, investors aim to seek justice and potentially recover losses sustained during this tumultuous period for Capricor Therapeutics.